Covered recipient · General Payments record
SABRINA BRANA
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2019–2024
$880.05
- Reported across 32 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $478.11 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $127.18 | 1 |
| PFIZER INC. | $88.57 | 4 |
| Lilly USA, LLC | $57.65 | 3 |
| Amgen Inc. | $47.01 | 2 |
| Novo Nordisk AS | $44.06 | 2 |
| Acerta Pharma LLC | $43.47 | 2 |
| SHIELD THERAPEUTICS INC | $38.03 | 2 |
| UCB, Inc. | $32.14 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $127.18 | 08/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125273354 | CMS |
| Amgen Inc. | $29.75 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117512543 | CMS |
| Amgen Inc. | $17.26 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115460991 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.23 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105564034 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.24 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105428406 | CMS |
| Lilly USA, LLC | $22.74 | 08/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135369478 | CMS |
| Lilly USA, LLC | $19.61 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135384601 | CMS |
| Lilly USA, LLC | $15.30 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135384599 | CMS |
| Novo Nordisk Inc | $20.53 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096694820 | CMS |
| Novo Nordisk Inc | $23.53 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096637874 | CMS |
| PFIZER INC. | $22.76 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131734212 | CMS |
| PFIZER INC. | $21.17 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131791147 | CMS |
| PFIZER INC. | $19.64 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132130921 | CMS |
| PFIZER INC. | $25.00 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131249390 | CMS |
| SHIELD THERAPEUTICS INC | $13.27 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150123467 | CMS |
| SHIELD THERAPEUTICS INC | $24.76 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150149767 | CMS |
| UCB, Inc. | $32.14 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143088276 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.